

Iben KÃ¼mler

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/39431/publications.pdf>

Version: 2024-02-01

20
papers

511
citations

840776

11
h-index

839539

18
g-index

21
all docs

21
docs citations

21
times ranked

1169
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic and Clinicopathologic Associations of LAG-3 Expression in Triple-negative Breast Cancer. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2022, 30, 62-71.	1.2	20
2	Automated Quantification of sTIL Density with H&E-Based Digital Image Analysis Has Prognostic Potential in Triple-Negative Breast Cancers. <i>Cancers</i> , 2021, 13, 3050.	3.7	21
3	PD-L1 diagnostics in the neoadjuvant setting: implications of intratumoral heterogeneity of PD-L1 expression in triple negative breast cancer for assessment in small biopsies. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 553-560.	2.5	29
4	Two open-label, single arm, non-randomized phase II studies of irinotecan for the treatment of metastatic breast cancer in patients with increased copy number of the topoisomerase I gene. <i>BMC Cancer</i> , 2019, 19, 573.	2.6	4
5	An open label phase 1 study evaluation safety, tolerability, and maximum tolerated dose of oral administration of irinotecan in combination with capecitabine. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 441-446.	2.3	3
6	Oral administration of irinotecan in patients with solid tumors: an open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokinetics. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 169-178.	2.3	12
7	Expression Patterns of Biomarkers in Primary Tumors and Corresponding Metastases in Breast Cancer. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2018, 26, 13-19.	1.2	5
8	Prediction of exemestane benefit in patients with advanced breast cancer based on diagnostic biopsy mRNA analysis.. <i>Journal of Clinical Oncology</i> , 2017, 35, e12532-e12532.	1.6	0
9	Specific CDK4/6 inhibition in breast cancer: a systematic review of current clinical evidence. <i>ESMO Open</i> , 2016, 1, e000093.	4.5	27
10	Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrant. <i>ESMO Open</i> , 2016, 1, e000062.	4.5	43
11	Clinical outcome of percutaneous RF-ablation of non-operable patients with liver metastasis from breast cancer. <i>Radiologia Medica</i> , 2015, 120, 536-541.	7.7	17
12	Topoisomerase- α 1 gene copy aberrations are frequent in patients with breast cancer. <i>International Journal of Cancer</i> , 2015, 137, 2000-2006.	5.1	14
13	A phase II study of weekly irinotecan in patients with locally advanced or metastatic HER2- negative breast cancer and increased copy numbers of the topoisomerase 1 (TOP1) gene: a study protocol. <i>BMC Cancer</i> , 2015, 15, 78.	2.6	9
14	Drug transporters in breast cancer: response to anthracyclines and taxanes. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 1075-1092.	2.4	6
15	A systematic review of dual targeting in HER2-positive breast cancer. <i>Cancer Treatment Reviews</i> , 2014, 40, 259-270.	7.7	141
16	A systematic review of bevacizumab efficacy in breast cancer. <i>Cancer Treatment Reviews</i> , 2014, 40, 960-973.	7.7	59
17	Use of microRNA to identify stage IV breast cancer patients to be targeted with phospholipase A2 disrupted cisplatin carrying liposomes: An ongoing phase I trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS1139-TPS1139.	1.6	0
18	A systematic review on topoisomerase 1 inhibition in the treatment of metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 138, 347-358.	2.5	54

#	ARTICLE	IF	CITATIONS
19	Biomarker-Guided Repurposing of Chemotherapeutic Drugs for Cancer Therapy: A Novel Strategy in Drug Development. <i>Frontiers in Oncology</i> , 2013, 3, 313.	2.8	42
20	Trials of bevacizumab in breast cancer – a safety review. <i>Expert Opinion on Drug Safety</i> , 2012, 11, S37-S48.	2.4	5